摘要:
The continuous liquid separation is a continuous liquid separating apparatus that separates a first liquid and a second liquid that is immiscible to the first liquid and has a higher specific gravity than the first liquid, and includes: a liquid separating tank configured to contain a liquid, and be supplied with a liquid mixture of the first liquid and the second liquid, and including a first discharge portion on a lower side thereof and a second discharge portion disposed at a position higher than the first discharge portion, a valve configured to open/close the first discharge portion, a first sensor configured to detect a first water level of the liquid mixture contained in the liquid separating tank, the first water level being lower than the second discharge portion, and a second sensor configured to detect a second water level of the liquid mixture contained in the liquid separating tank.
摘要:
A new preventive and therapeutic agent given by oral administration containing carnosine zinc salt as the effective component and, effective against alcoholic liver disorder, viral hepatitis or liver disorders caused by drugs, toxicants, radiation, etc.
摘要:
An object of the present invention is to provide a method for producing an optically active amino acid in high yield and in a highly enantioselective manner, which method has fewer restrictions on the material that can be used as the substrate, and to provide, among others, a compound useful as a chiral auxiliary for the method. The present invention provides an N-(2-acylaryl)-2-[5,7-dihydro-6H-dibenzo[c,e]azepin-6-yl]acetamide compound represented by Formula (1): or a salt thereof, or a metal complex represented, by Formula (3):
摘要:
An agent for the prevention and treatment of inflammatory bowel disease (IBD) containing at least one of zinc L-carnosine salts and complexes as an active ingredient. A use of the zinc L-carnosine salts or complexes and a therapeutic method of IBD by using the same are also disclosed.
摘要:
Novel porphyrin derivatives of the general formula: ##STR1## wherein R.sub.1 each independently denotes a hydrogen, a C.sub.1 -C.sub.4 alkyl group or an ethenyl group, and R.sub.2 each independently denotes COZ(C.sub.m H.sub.2m)Q, COZCH(C.sub.m H.sub.2m Q).sub.2, --CH.sub.2 --Q [wherein Z is O, S or NH, m is an integer of 1 to 23, and Q is a di-(C.sub.1 -C.sub.4 alkyl)amino group or tri-(C.sub.1 -C.sub.4 alkyl)ammonium halide group] or ##STR2## (wherein X is a halogen); or R.sub.1 each independently denotes --C.sub.2 H.sub.4 --Q (wherein Q is the same as defined above), ##STR3## (wherein X is the same as defined above), and R.sub.2 each independently denotes a carboxyl group or a C.sub.1 -C.sub.4 alkoxycarbonyl group, and the production thereof are described. The quarternary ammonium salt type of the above compounds exhibit affinity and photosensitizing activity for cancer cells and can be employed for diagnosing and treating cancer under irradiation of laser light.
摘要:
Provided are a novel chiral iridium(III) complex; and a method for producing optically active 2-substituted-1,2,3,4-tetrahydroquinolines from 2-substituted-quinolines with the use of the chiral iridium(III) complex through a more economical and easy production process. The disclosed method for producing optically active 2-substituted-1,2,3,4-tetrahydroquinolines comprises reducing a quinoline compound represented by formula [I]: in the presence of a hydrogen donor compound and an iridium (III) complex having a chiral prolinamide compound as a ligand to give an optically active 2-substituted-1,2,3,4-tetrahydroquinoline represented by formula [II]:
摘要:
Provided are a novel chiral iridium(III) complex; and a method for producing optically active 2-substituted-1,2,3,4-tetrahydroquinolines from 2-substituted-quinolines with the use of the chiral iridium(III) complex through a more economical and easy production process. The disclosed method for producing optically active 2-substituted-1,2,3,4-tetrahydroquinolines comprises reducing a quinoline compound represented by formula [I]: in the presence of a hydrogen donor compound and an iridium (III) complex having a chiral prolinamide compound as a ligand to give an optically active 2-substituted-1,2,3,4-tetrahydroquinoline represented by formula [II]:
摘要:
The present invention relates to an antibacterial agent, which comprises, as an active ingredient, a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof.
摘要:
There are provided quaternary ammonium compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2, each independently represents a hydrogen atom, a C.sub.1 to C.sub.8 lower alkyl or alkenyl group, or C.sub.3 to C.sub.8 lower cycloalkyl, cycloalkenyl, aralkyl or aryl group; or R.sub.1 and R.sub.2 combine with each other in combination with the adjacent N and carbon atoms or further with at least one of nitrogen, oxygen and sulfur atoms to represent a 3- to 8- membered heterocyclic ring group: R.sub.3, R.sub.4 and R.sub.5, each independently represents a C.sub.1 to C.sub.8 lower alkyl or alkenyl group, C.sub.3 to C.sub.8 lower cycloalkyl, cycloalkenyl, aralkyl or aryl group; or either two of R.sub.3, R.sub.4 and R.sub.5 combine with each other in combination with the adjacent N and carbon atoms or further with at least one of nitrogen, oxygen and sulfur atoms to represent a 3- or 8-membered heterocyclic ring group, with the remaining being the same as defined in the above; or R.sub.3, R.sub.4 and R.sub.5 combine with one another in combination with the adjacent N to represent a nitrogen-containing bicyclo ring or nitrogen-containing aromatic ring group: n is an integer of 1 to 8; and x.sup.- represents an anion being capable of forming a quaternary ammonium group.The compounds are useful in treatment of ulcer in mammals.
摘要:
A novel crystalline L-carnosine zinc complex is produced by reacting L-carnosine, a zinc salt and an alkali metal compound in an anhydrous or hydrous polar organic solvent.The crystalline L-carnosine zinc complex substantially corresponds to the formula C.sub.9 H.sub.12 N.sub.4 O.sub.3 Zn and has physical properties clearly different from the known amorphous L-carnosine zinc complex.As compared with the amorphous complex, the crystalline complex is very low in impurity, stable to heat and moisture, and easy to filtrate, and has higher anti-ulcer activity.